Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Neoplasm, Residual 3Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Colorectal Neoplasms 2Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1Burkitt Lymphoma 1

Interventions

Rituximab 78Cyclophosphamide 76fludarabine phosphate 45Peripheral Blood Stem Cell Transplantation 41Mycophenolic Acid 39Tacrolimus 35Whole-Body Irradiation 33Radiotherapy 29Busulfan 29Cyclosporine 27Antilymphocyte Serum 27Etoposide 25Filgrastim 24Methotrexate 22Melphalan 22Lenalidomide 15Cytarabine 15Cord Blood Stem Cell Transplantation 14fludarabine 13Methylprednisolone 13Bortezomib 13orelabrutinib 12Dexamethasone 12sargramostim 11obinutuzumab 11Sirolimus 9Carmustine 9venetoclax 8Vincristine 8Prednisone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell, Marginal Zone × Maintenance × Clear all
NCT07372365 2026-01-28

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
23 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡